When does the patent for wegovy expire?

What triggers the patent expiration for Wegovy?

The patent for Wegovy, also known as semaglutide, is owned by Novo Nordisk [1]. The patent for semaglutide in the EU is set to expire in 2030, but the US patent is set to expire in 2035 [1].

How does Novo Nordisk's patent strategy affect the market?

A key factor is Novo Nordisk's plan to offer a lower-cost, authorized generic version of Wegovy after the US patent expires in 2035 [2].

What side effects are patients asking about?

Wegovyy has been associated with potential side effects like nausea, vomiting, and diarrhea, and the patent expiration may influence the development of biosimilars and generic versions [1].

Will other companies be able to market biosimilars of Wegovy before the patent expires?

The FDA has approved several applications for other companies to market biosimilars of semaglutide in the United States, but a decision has not been made yet on when they may come to market [3].

Sources:

[1] DrugPatentWatch.com: Novo Nordisk's semaglutide patent

[2] Novo Nordisk to offer authorized generic version of Wegovy

[3] FDA approves several biosimilars of semaglutide